Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Sempra Energy (SRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Sempra Energy — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Sempra Energy trades at $82.38 (market cap $53.86B). The key difference: Sempra Energy is far larger — about 6.1× Kymera Therapeutics Inc. Common Stock's market cap, and Sempra Energy pays a 3.19% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Sempra Energy for 9 Days on average.
| KYMR | SRE | |
|---|---|---|
Market Cap | $8.87B | $53.86B |
Volume | 779,107 | 2,605,713 |
Sector | Health | Utilities |
52-Week High | $127.31 | $99.75 |
52-Week Low | $55.80 | $76.90 |
Typical Hold Time | 0 Days | 9 Days |
Enterprise Value | $8.26B | $90.50B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sempra Energy (SRE) trades at $82.37, up 0.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong Q2 2026 earnings that beat expectations, with a net income margin of 16.83% and robust cash flow from operations of $5.4 billion in 2026. Recent developments include a 20-year LNG supply agreement with Petrobras and the opening of SoCalGas' new headquarters, signaling growth initiatives.
The outlook for SRE is positive, supported by analyst consensus with an 80.77% buy rating and a price target of $97.25, implying significant upside. Key opportunities include EPS growth guidance of 7–9% and strategic investments in Texas and LNG. Risks involve high capital expenditures, regulatory exposure, and interest rate sensitivity. The stock's current valuation at a P/E of 23.88 requires continued execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Sempra Energy
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →
